To view the PDF file, sign up for a MySharenet subscription.

ASPEN PHARMACARE HOLDINGS LIMITED - Investigation By UK Competition Authority

Release Date: 13/10/2017 17:00
Code(s): APN     PDF:  
Wrap Text
Investigation By UK Competition Authority

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)(“Aspen Holdings”)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen”)



INVESTIGATION BY UK COMPETITION AUTHORITY

Shareholders are advised that the the UK Competition and Markets Authority (“CMA”) has opened
an investigation against Aspen into alleged anti-competitive conduct in relation to the supply of
Fludrocortisone acetate 0.1 mg tablets and Dexamethasone 2 mg tablets in the UK. In 2016 the two
products had a combined revenue of GBP11.1 million in the UK.

The investigation is at an early, information-gathering stage and the CMA has confirmed that, at this
time, it has not reached any conclusion on whether competition law has been infringed.

While Aspen is not currently in a position to comment on this investigation, it reaffirms its
commitment to fair and open competition in the UK and around the world. Aspen takes compliance
with competition laws very seriously and will work constructively with the CMA in its process.

Shareholders are advised that any material developments in these proceedings will be
communicated through SENS. Shareholders should exercise care when reacting to information on
this matter which has not been released by Aspen Holdings.

Durban
13 October 2017

Sponsor:
Investec Bank Limited




About Aspen

Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and
promoting healthcare through increasing access to its high quality affordable medicines and
products.

As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive
basket of products that provide treatment for a broad spectrum of acute and chronic conditions
experienced through all stages of life. The Group continues to increase the number of lives
benefitting from its products, reaching more than 150 countries. In line with the Group’s
commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics,
high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the
highest focus based on materiality and future potential.
Aspen has a strong presence in both emerging and developed countries with more than 60
established business operations in approximately 50 countries.

Aspen holds international manufacturing approvals from some of the most stringent global
regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are
scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids,
semi-solids, steriles, biologicals, APIs and infant nutritionals.

Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical
company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies
on this exchange. For more information visit: http://www.aspenpharma.com/

Date: 13/10/2017 05:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story